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Abstract
Background: Subtelomeric regions dynamically change their epigenetic pattern during development and
progression of several malignancies and degenerative disorders. However, DNA methylation of human
subtelomeres and their correlation to telomere length (TL) remain undetermined in glioma.
Results: Herein, we report on the selective changes in subtelomeric DNA methylation at the end of five
chromosomes (Chr.) (7q, 8q. 18p, 21q, and XpYp) and ascertain their correlation with TL in patients with glioma.
Subtelomeric methylation level was invariably higher in glioma patients compared to the control group, irrespective
of their age and tumor grade. In particular, a significant increase in methylation was observed at the subtelomeric
CpG sites of Chr. 8q, 21q, and XpYp in tissues, obtained from the brain tumor of glioma patients. In contrast, no
significant change in methylation was observed at the subtelomere of Chr. 7q and 18p. Selective changes in the
subtelomeric methylation level, however, did not show any significant correlation to the global TL. This observed
phenomenon was validated in vitro by inducing demethylation in a glioblastoma cell line (SF-767) using 5-azacytidine
(AZA) treatment. AZA treatment caused significant changes in the subtelomeric methylation pattern but did not alter
the TL, which supports our hypothesis.
Conclusions: DNA methylation level dramatically increased at the subtelomere of Chr.8q, 21q, and XpYp in malignant
glioma, which could be used as an early epigenetic diagnostic biomarker of the disease. Alterations in subtelomeric
methylation, however, have no effects on the TL.
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Background
Malignant glioma is one of the most common, locally in-
vasive and aggressive form of primary brain tumors that
predominantly manifests in adults but is also frequently
reported in infants [1, 2]. In its most aggressive mani-
festation, glioblastoma multiforme, the median survival
of patients is approximated to a year, and survivors over
3 years are referred to as the “long-term survivors” [3,
4]. Despite the accessibility to multimodal therapeutics
including surgery, chemotherapy and radiation therapy,
the overall therapeutic benefit against glioma remains
unsatisfactory [5]. One of the major focuses in clinical
research hence has been aimed to identify the potential
early stage signatures imprinted at the genomic or epige-
nomic loci of glioma [6]. The modified epigenetic marks
such as DNA hypermethylation or hypomethylation of
different gene promoters are already reported from sev-
eral clinical studies in conjunction with glioma patients
[7–9]. In particular, the occurrence of hypermethylation at
the MGMT (O6-methylguanine DNA-methyltransferase)
promoter, located at Chr. 10q26, has been identified as
one of the significant molecular markers of glioma [10].
The acquired methylation at the MGMT promoter results
in silencing of the gene, which has been associated with
prolonged survival in glioma patients, due to the enhanced
susceptibility of tumor cells to the chemotherapeutic
agents such as temozolomide [11, 12]. Besides MGMT,
hypermethylation at the promoter of several tumor sup-
pressors, apoptotic, or Wnt-signaling pathway involved
genes and hypomethylation of normally silenced genes
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such as CD133, MMP9, or IL8 have also been identified
among the glioma patients [13–15].
Telomeres positioned at the ends of chromosomes are
specialized nucleoprotein complexes containing multiple
arrays of duplex TTAGGG repeats and a complex of
telomere repeat binding proteins [16, 17]. Telomeres
prevent degradation of chromosome (Chr.) ends and
their exposure to unnecessary DNA repair activities and
recombinations [16]. Telomere adjacent subtelomeric
domains are also considered to be a part of heterochro-
matic regions [18], which are enriched with the pro-
moters of several genes, segmental duplications, satellite
sequences, or telomere-like interstitial TTAGGG repeat
sequences. In addition, subtelomeres harbor highly re-
petitive CpG dinucleotides, which are otherwise absent
in telomeres and are prone to epigenetic changes, mainly
the DNA methylation. Aberrant epigenetic alterations at
the subtelomeric CpGs due to induced methylation or
hydroxymethylation have been reported to influence sev-
eral biological pathways or induce cellular reprogram-
ming; the detailed mechanisms of which are yet to be
understood [19]. The random epigenetic modifications
at the subtelomeric repeat elements or embedded gene
promoters are also speculated to influence telomere
length (TL), which is otherwise tightly regulated [18, 20].
Several studies have suggested that dense cytosine
methylation at the subtelomeric CpG islands may be in-
volved in silencing the noncoding RNA referred to as
the telomere repeat-containing RNA (TERRA), a poten-
tial negative regulator of telomerase. Methylation medi-
ated transcriptional repression of the TERRA promoter,
embedded in the subtelomeric regions may facilitate tel-
omerase access resulting in telomere lengthening in tel-
omerase positive tumor cells [21–23]. In contrast, triple
negative knockdown of Ten eleven translocation (TET)
methylcytosine deoxygenase proteins in mouse embry-
onic stem cells, which caused depletion of methylated
cytosines in the chromosomal ends, is reported to result
in elongated telomere [24]. Moreover, some recent re-
ports have demonstrated the correlation between the
subtelomeric DNA methylation to the development of
several degenerative disorders and some sporadic malig-
nancies [25–27]. In summary, studies show that DNA
methylation of subtelomeric regions plays a crucial role
in the regulation of TL [28].
Acquired hypermethylation at the promoter of several
neural and proneural genes have also been identified
during the occurrence and progression of glioma [7, 8,
29]. However, to the best of our knowledge, changes in
the DNA methylation of human subtelomeres and their
correlation to TL remain undetermined in glioma.
Herein, we report the occurrence of selective increase in
methylation at the subtelomeric CpG sites of specific
chromosomes in a cohort of glioma patients, which
could serve as potential epigenetic biomarker for the dis-
ease. In addition, we have evaluated the correlation be-
tween the changes in DNA methylation at the
subtelomeric loci to the global TL.
Methods
Cell and tissue samples
Tissue samples were collected from the non-glioma pa-
tients (n = 13), who were subjected to surgeries for se-
vere accidental injuries in the brain. In contrast, tissue
samples from the glioma patients (n = 15) were obtained
from tumor tissues, resected after neurosurgery. Tumor
grade was determined by a certified pathologist accord-
ing to the 2007 World Health Organization (WHO)
Classification of Tumors of the Central Nervous System.
Tissue samples were frozen directly in liquid nitrogen
and stored at −80 °C. Glioma tissue biopsies were
collected from patients of different demographic and
clinicopathologic features from the Xiangya Hospital
of Central South University at Hunan province,
China. Informed consent was obtained from all of the
involved patients. This study was approved by the
Ethical Committee of Xiangya Hospital of Central South
University. In addition to patient tissue samples, we have
also used a standard glioblastoma cell line SF767 in the
present study for in vitro cross validation of the observed
correlation between change in subtelomeric DNA methy-
lation and TL.
Extraction of genomic DNA
Genomic DNA from control or tumor tissues were iso-
lated in cell lysis buffer (100 mM Tris-HCl, 5 mM
EDTA, 0.2 % SDS, 200 mM NaCl, 0.667 μg/μl Proteinase
K) at 55 °C overnight. In the second day, samples were
added with an equal volume of phenol:chloroform:isoa-
myl alcohol (25:24:1 saturated with 10 mM Tris, 1 mM
EDTA), mixed evenly and centrifuged for 5 min at
14,000g. The supernatant was then transferred into a
new tube and precipitated with equal volume of 100 %
isopropanol. The genomic DNA was recovered and dis-
solved with 10 mM Tris-HCl. Genomic DNA samples
were further sonicated into 500 bp by Misonix sonicator
3000. The concentration of sonicated DNA was then de-
termined by a Nano-Drop 1000 system (Thermo Scien-
tific, USA). DNA integrity and RNA contamination were
assessed by gel electrophoresis.
Determination of global change in DNA methylation
Genome-wide methylation level (5-mC %) in both the
control and glioma patients were determined with Methyl-
Fash Methylated DNA Quantification Kit (Epigentek,
NY, USA) according to manufacturer’s protocol.
Briefly, genomic DNA was extracted from the tissue
samples (as mentioned above), and 5-mC% was
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determined out of 100 ng of the DNA in triplicate. A
methylated and unmethylated DNA (20 μg/ml each)
sample was used as positive and negative control, re-
spectively, and for determining the relative methyla-
tion level for each patient in the tested groups.
Bisulfite conversion of genomic DNA
Genomic DNA isolated from the tissue or cell samples
were bisulfite converted using the EZ DNA methylation
kit (Zymo Research, CA, USA). Briefly, 500 ng of DNA
sample was mixed with 5 μl of M-dilution buffer in the
total volume of 50 μl and incubated at 37 °C for 15 min.
One hundred microliters of Cytosine to Thymidine (CT)
conversion agent was then added to the samples and in-
cubated further at 50 °C for 14–16 h. Modified DNA
was purified using Zymo spin columns along with the
provided buffers in the kit. The bisulfite converted DNA
samples were then eluted in 10 μl of elution buffer and
evaluated for DNA concentration.
Methylation specific PCR
Subtelomeric methylation level was primarily deter-
mined in triplicate using methylation specific polymerase
chain reaction (methylation specific PCR (MSP)) and
expressed as the methylation ratio (%). Methylation and
unmethylation ratio from the band intensities of the gel
images were calculated, as described in the previous
study. For this study, methylation ratio over 50 % was
considered hypermethylated, and less than 50 % was
considered hypomethylated [27]. MSP primers were se-
lected against the subtelomeric regions of five different
chromosomes namely 7q, 8q, 18p, 21q, and XpYp, re-
ported elsewhere [27]. MSP was carried out using the
Pyromark PCR kit (QIAGEN, CA, USA) according to
manufacturer’s specification. Briefly, 20 ng of bisulfite
converted DNA was mixed with 1 X Pyromark PCR
master mix, 1× coral load solution, 1 μM MgCl2, 0.2 μM
primer (each), and adjusted with water to constitute a
reaction volume 25 μl. PCR reaction conditions were
retained as in the original report. PCR products were re-
solved in 2 % agarose gels, and the band intensities were
analyzed with the ImageJ software (National Institutes of
Health, Bethesda, MD, USA; http://rsb.info.nih.gov/ij/).
Amplicon size for all the observed subtelomeric regions
were less than 500 bp. A 100-bp DNA ladder was used
in each case for convenience.
Bisulfite PCR and pyrosequencing
Bisulfite PCR (BSP) and pyrosequencing primers were
designed against the region that flanks over the MSP
amplicons, to quantitatively determine the percentage of
methylation difference at the target CpG sites between
the control and glioma patients using the Pyromark
Assay Design tool (Sw2, QIAGEN, CA, USA). PCR
primers, reaction conditions, sequencing primers, and
target genomic sequences are summarized in Add-
itional file 1: Table S1 and S2.
Telomere length measurement
A quantitative real-time PCR (qPCR) was performed in
MicroAmp optical 96-well reaction plates using StepO-
nePlus Real-Time PCR Systems (v 2.0, Applied Biosys-
tems) to determine the TL of the genomic DNA from
both the cell line or patient tissue samples. All qPCR as-
says were run in triplicate with a total reaction volume of
20 μl comprising of 1× Power SYBR Green PCR Master
Mix (Life Technologies, USA), 200 nM of both the for-
ward (CGGTTTGTTTGGGTTTGGGTTTGGGTTTGG
GTTTGGGTT) and reverse (TTGCCTTACCCTTACCC
TTACCCTTACCCTTACCCT) primers (Integrated DNA
technologies, IA, USA), and 2 μl of target DNA solu-
tion adjusted to the total reaction volume. TL length
was determined, followed by the existing standard guide-
lines [30, 31] with slight modifications. Initially, a standard
curve was prepared by plotting the cycle threshold (CT)
values against six different dilutions (500, 250, 100, 50, 5,
and 0.5 pg, respectively) of a telomere oligomer standard
(TTAGGG repeated for 14 times; IDT, USA), amplified
with the aforementioned primer set. For the test samples,
a uniform DNA concentration (20 ng) was maintained by
adjusting the volume with PUC-19 plasmid instead of
PBR3222, as mentioned in the previous report [31]. Each
tube hence contained equal amount of DNA but differen-
tially concentrated telomeric DNA. The CT values, ob-
tained from different test samples were then fitted to the
telomere standard curve to determine the TL (T) expressed
as [log (kb)] / reaction. In addition, the CT value from the
single copy gene 36B4 was used to determine the number
of diploid genome (S), and the final TL was expressed in
terms of total length of telomere (in kilobase) per human
diploid genome (T/S). T/S values were occasionally repre-
sented in kilobase (adjusted with the formula) [32], when
required to mention the absolute value of TL.
Cell line studies and treatment with 5-azacytidine
Human glioblastoma cell line SF-767 was cultured in
Iscove’s modified Dulbecco’s medium (IMDM) supple-
mented with 10 % fetal bovine serum, 1 % antibiotics,
and 1 % glutamate at 37 °C. After the cells reached 80 %
confluence, 3 μM 5-azacytidine (AZA) was prepared
with fresh medium and the cells were treated for 72 h
and the cell viability was monitored. Cells treated with
DMSO were used as a negative control.
Statistical analysis
To determine the difference between average mean
methylation levels and to analyze the independence of
CpG methylation between the control and glioma
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patient groups, a two tailed Mann–Whitney U test was
performed. The coefficient of variation (Cv) between dif-
ferent round of experiments for MSP and pyrosequenc-
ing analyses are mentioned in the supplementary note of
SI. Pearson’s correlation coefficient (R) was used to
evaluate the strength of association between TL (T/S)
and levels of DNA methylation at different subtelomeric
CpG sites from the selected chromosomes. Multivariate
linear regression analysis was performed to adjust the
potential confounders and test of interaction. A p value
of <0.05 was considered statistically significant for all the
obtained data.
Results
Correlation between patient characteristics and
subtelomeric methylation
The demographic and clinicopathological features of pa-
tients, enrolled in this study, are summarized in Table 1.
Since the sample size of the present study was relatively
small, we cannot predict the statistical correlation be-
tween the occurrence of glioma in relation to age or
gender. However, we have assessed the difference in sub-
telomeric methylation level (%) at five chromosomes be-
tween the control (non to –glioma) and glioma patients
for three age groups (<30 y, 30–60 y, and >60 y) (Add-
itional file 1: Figure S1 and S2). In non-glioma patients,
subtelomeric methylation levels were either gradually re-
duced over the ages, such as in Chr. 7q, 8q, and XpYp
or remained almost unchanged such as in Chr.18p and
21q. In contrast, we observed high methylation level at
the subtelomeric CpG sites among glioma patients, at all
age groups. Although the methylation level did not show
any significant alteration among the groups categorized
on the basis of clinicopathological features such as
tumor grade or tissue position but were invariably higher
in glioma patients compared to the control patients
(data not shown). In summary, subtelomeric methylation
levels were consistently higher in glioma patients at all
age groups, addressed in this study, and the change in
methylation level can be detected even at the early stage
of glioma (grade-II). These features propose the selective
subtelomeric sites to be considered as the key bio-
markers of glioma.
Global methylation vs subtelomeric methylation level
The percentage of genome-wide 5-methylcytosine (5-
mC %) in the cohort of control patients was in the range
between 0.89 and 1.3 %, with the median value of
1.11 %. The 5-mC % assessed in the samples from gli-
oma patients was distributed between 0.9 and 1.4 %,
with a median value of 1.2 %. However, we did not find
any statistically relevant difference (p = 0.81) in the mean
5-mC level between the non-glioma (1.08 ± 0.28 %) and
glioma (1.19 ± 0.39 %) patients (Additional file 1: Figure
Table 1 Demographic and clinicopathologic characteristics of
control and glioma patient cases
Variables Control (n= 13) Glioma (n = 15)
Gender
Male 12 (92.3 %) 8 (53.34 %)
Female 1 (7.69 %) 7 (46.67 %)
Age (year)
< 30 2 (15.38 %) 5 (33.34 %)
30–60 7 (53.84 %) 8 (53.34 %)
> 60 4 (30.76 %) 2 (13.34 %)
Smoking (in last 5 year)
Smoker 2 (15.38 %) 2 (13.34 %)
Non-smoker 11 (84.61 %) 13 (86.67 %)
Education level
High school and above 5 (38.46 %) 8 (53.34 %)
Below high school 8 (61.53 %) 7 (46.67 %)
Income level (annual)
< $5000 9 (69.23 %) 11 (73.34 %)
$5000–$10,000 1 (7.68 %) 2 (13.34 %)
> $10,000 3 (23.07 %) 2 (13.34 %)
Biopsy tissue positiona
Frontal 7 (53.84 %) 7 (46.67 %)
Temporal 5 (38.46 %) 4 (26.67 %)
Parietal 0 2 (13.34 %)
Occipital 1 (7.69 %) 3 (20 %)
Othersb 0 2 (13.34 %)
WHO tumor grade
Low-grade glioma (II) NA 5 (33.34 %)
Malignant glioma (III) NA 6 (40 %)
Glioblastoma (IV) NA 4 (26.67 %)
Post-surgery treatmentc
Radiotherapy NA 1.8 Gy/d (total dose,
50–60 Gy, including
30–36 Gy for brain/spine
and 20 Gy for tumor
local boost
Chemotherapy NA Oral administration of
temozolomide
(150 mg/m2/d) for
first 5 days in a
28-day cycle (total 8 cycles
of treatment)
NA not applicable
aBrain biopsy tissues from three glioma patients were obtained from more
than one location. Example includes one of the patients had tumor growth in
both frontal and temporal lobe, while two other patients had tumor growth in
both parietal and occipital lobe
bOther positions of biopsy tissue samples include regions such as the fourth
ventricle and cerebellum
cIndividuals that belong to both the cohort of normal and glioma patients
were considered based on the criteria that they had no history of other
chronic diseases or known long-term exposure to any drugs
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S3). On the contrary, much interesting and diverse re-
sults were obtained from the methylation pattern at the
observed subtelomeric regions. The subtelomere of Chr.
7q was found to be partially methylated in both the
groups, since the amplification was observed against
both the methylation (M)- and unmethylation (U)-spe-
cific primers. However, the methylation level for both
the groups was determined to be over 50 % (hyper-
methylated). The mean methylation level in non-glioma
individuals (65.62 ± 10.10 %) did not significantly differ
from the glioma patients (75.05 ± 13.38 %) (Figs.1a and
2a). The subtelomere of Chr. 8q was also partially meth-
ylated but showed reduced methylation level (<50 %) in
both the groups. The difference in the mean methylation
of glioma (16.58 ± 14.1 %) and non-glioma (12.03 ±
6.70 %) groups was not significantly different (Figs.1b
and 2b). The subtelomeric domain of Chr. 18p was par-
tially methylated with the difference in mean methyla-
tion between the non-glioma to glioma patients were
35.39 ± 10.10 % and 79.68 ± 14.25 %, respectively, which
exhibit a statistically significant difference (Figs.1c and
2c). In contrast, the CpG sites at the subtelomeres of
Chr. 21q and XpYp showed a general trend in hypome-
thylation (<50 %) among the non-glioma patients and
hypermethylation (>50 %) among the glioma patients.
The mean methylation level in non-glioma to glioma pa-
tients varied from 17.92 ± 11.25 % to 77.70 ± 21.34 % in
chromosome 21q (Figs.1d and 2d) and 26.10 ± 13.80 %
to 86.23 ± 19.60 % in chromosome XpYp (Figs.1e and
2e). The mean differences in methylation level percent-
age between the groups for these two chromosomes
hence can be considered significant.
CpG specific changes in methylation at the subtelomeres
The observed changes in methylation through MSP were
cross-validated by quantitatively determining the per-
centage of methylation at each CpGs of the observed
subtelomeric sites, using pyrosequencing analysis. The
difference in the mean methylation at Chr. 7q subtelo-
mere between the non-glioma (90.34 ± 5.50 %) and gli-
oma patients (92.5 ± 1.72 %) was found to be
insignificant (p = 0.67) (Fig. 2f ), which was consistent to
the MSP data. Moreover, no significant change in
methylation was observed in four out of six CpG sites
(except for CpG1 and CpG6) between the non-glioma
and glioma patients (Fig.3a). A conflicting result was ob-
tained from MSP and pyrosequencing analyses relating
to the mean methylation level at Chr.8q subtelomere.
MSP data showed insignificant (p = 0.08) difference in
the average mean methylation level between the groups,
while the pyrosequencing analysis revealed the change in
mean methylation level from 1.4 ± 0.57 % to 11.5 ±
2.25 % between the control and glioma patients, which
was significant (p < 0.05) (Fig. 2g). Nonetheless, five of
the six CpG sites were significantly methylated in the
glioma group (Fig.3b). The change in methylation at five
CpG sites hence makes this region a suitable candidate
as a biomarker of the disease. The change in methylation
level between the test groups at the Chr. 18p subtelo-
mere also showed disparity between MSP and pyrose-
quencing as the Chr. 8q. The mean methylation
difference between the non-glioma (66 ± 5.62 %) and gli-
oma groups (72.2 ± 3.53 %) were statistically insignificant
(p = 0.09), as obtained from the pyrosequencing (Fig. 2h),
which was inconsistent with the results from MSP
(Fig. 2c). Two of the six CpGs (CpG1 and CpG3) in 18p
subtelomere were significantly methylated only in glioma
patients (Fig.3c). In contrast, the mean methylation level
from non-glioma to glioma patients changed from 13.25
± 4.7 % to 51.97 ± 15.45 % in chromosome 21q (Fig. 2i)
Fig. 1 A representative result of methylation specific PCR (MSP) in
the subtelomeric region on Chr. 7q (a), 8q (b), 18p (c), 21q (d), and
XpYp (e). M and U refers to the amplification from the methylation- and
unmethylation-specific primers respectively. Representative patients
were identified by numbers. Chr. 7q subtelomere was partially
methylated, and methylation level did not change significantly
between the control and glioma patients. Chr.8q subtelomere was
also partially methylated, but the methylation ratio increased
significantly among the glioma patients. Chr. 18p subtelomere in
majority of the non-glioma patients was noticeably amplified with U
primers. However, distinct M-specific amplification was observed
among the glioma patients. In contrast, subtelomeres of Chr. 21q and
XpYp were mostly unmethylated in the non-glioma patients but
showed significant increase in methylation level among the
glioma patients
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and from 28.5 ± 8.29 % to 62.7 ± 20.34 % in chromosome
XpYp (Fig. 2j), both of which were considered to have a
significant difference in methylation. Moreover, all of the
CpG sites at these two chromosomes were significantly
methylated in glioma patient groups (Fig.4a, b). Based
on these findings, it can be summarized that selective in-
crease in subtelomeric methylation at Chr. 8q, Chr.21q
and Chr. XpYp could serve as potential epigenetic bio-
markers of glioma.
Correlation between subtelomeric methylation and
telomere length
The relative TL (T/S) ranged from 6.17 to 7.71 kb, with
a mean of 7.0876 ± 0.45 kb in non-glioma patients, and
ranged from 6.27 to 7.96 kb, with the mean of 7.14 ±
0.57 kb in glioma patients (Fig. 5a). The mean change in
relative TL was not significantly different (p = 0.41) be-
tween the test groups. Simultaneously, we have also de-
termined the correlation between the subtelomeric
methylation level (%) at five chromosome ends to the
change in global TL in both the control and glioma pa-
tients. However, no linear correlation was established
between these two parameters. Moreover, the correla-
tions between the methylation levels from individuals in
each group to the corresponding TLs were also not sig-
nificant (Fig. 5b, f ). Based on these observations, we
hypothesize that changes in subtelomeric methylation do
not influence TL in glioma.
Induced demethylation and its correlation to the
telomere length
To cross validate the lack of correlation between TL and
subtelomeric methylation in glioma, a global demethyla-
tion was induced in SF-767 cells with AZA. Subtelo-
meric methylation level at each of the chromosomes was
then determined alongside the global TL, before and
after the drug treatment. The band intensity of the de-
methylation specific amplicons from the subtelomeric
regions of each chromosome was found to increase upon
drug treatment (Fig.6a). We have also determined the
change in demethylation ratio among the AZA-treated
genomic replicates over the negative control (Fig.6b).
The highest increment in the demethylation ratio was
observed for chromosome 8q, followed by XpYp, 7q,
Fig. 2 The difference in subtelomeric DNA methylation ratio, as obtained from MSP between control and glioma patients were found significant
for Chr. 18p (c), 21q (d), and XpYp (e). In contrast, insignificant alteration in methylation ratio was observed at the subtelomere of Chr. 7q (a) and
8q (b). The change in subtelomeric methylation level was cross-validated with pyrosequencing analysis. In comparison to MSP, pyrosequencing
data revealed significant change in average methylation level at Chr. 8q (g), 21q (i), and XpYp (j) but insignificant methylation alteration for Chr.
7q (f) and 18p (h)
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21q, and 18p. However, we have noticed no significant
change in the TL (T/S) between the untreated (2.346 ±
0.034) and AZA-treated (2.358 ± 0.049) cells (Fig. 6c).
These lines of experiments served as the in vitro valid-
ation of the observed phenomenon in the clinical iso-
lates and also support the claim that there may not be
any significant correlation between subtelomeric DNA
methylation level and global change in TL in glioma.
Discussion
Majority of cancer cells utilize telomerase to maintain
the TL through the recurrent recruitment of TTAGGG
repeat sequences at the chromosome ends [33]. Tel-
omerase is the ribonucleoprotein enzyme responsible for
DNA polymerization at telomeres and helps to over-
come the end-replication problems associated with pro-
gressive cell divisions [34]. However, a subset of tumors
including malignant glioma in adults utilize alternative
lengthening of telomeres (ALT) to sustain their self-
renewal activity, which involves recombination-mediated
replication of telomeric DNA [35, 36]. The occurrence
of subtelomeric DNA hypomethylation is often defined
as a favorable inducer of ALT [37]. However, a plethora
of reports are available, which do not support this claim
Fig. 3 The changes in methylation level (%) were quantitatively
determined at each of the CpG sites by pyrosequencing. Significant
changes in the percentage of methylation were observed in two out
of six CpGs in Chr. 7q (a), five out of six CpGs in Chr. 8q (b), and two
out of six CpG sites in Chr. 18p (c). Methylation in glioma and
control patients is presented with green and red colored
box-plots, respectively
Fig. 4 The changes in methylation level (%) were quantitatively
determined at each of the CpG sites in Chr. 21q (a) and Chr. XpYp
(b). In both the chromosomes, we have observed significant
increase in methylation level among glioma patients in comparison
to the group of control patients. Methylation in glioma and
control patients is presented with green and red colored
box-plots, respectively
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[38, 39]. It was found that instead of loss in methylation,
subtelomeres may acquire dense methylation in some
specific cell lines such as in SK-LU-1, towards telomere
lengthening [21]. These cumulative findings strongly
suggest that subtelomeric DNA methylation pattern
might vary from one cell line to the other and also varies
in different type of cancers, and hence, can be rationally
used as epigenetic biomarker of specific malignancies
[21, 27, 40]. Previously, variation in methylation pattern
for the same subtelomeric regions was reported in
regard to hepatocellular carcinoma [27]. The present
study reports the selective changes in methylation level
at these subtelomeric CpG sites for malignant glioma.
From our results, we observed that the subtelomere of
Chr.7q was hypermethylated, whereas hypomethylation
was observed at Chr. 8q, 18p, 21q, and XpYp subtelo-
meres in control patients. Nonetheless, significant in-
crease in subtelomeric methylation level was observed
for all the chromosomes in the glioma patients. The sig-
nificant change in the methylation level during
Fig. 5 Relationship between subtelomeric methylation status and telomere length in glioma. a Relative telomere length (T/S), expressed as the
relative ratio of the copy number of telomeric repeats to a single copy gene 36B4, in both control and glioma patients. Correlation between
telomere length (TL) and subtelomeric methylation ratio (as obtained from MSP) at five chromosomal ends was evaluated in both the control
and glioma patients (b–f). Methylations in glioma and control patients are presented with pink dots and blue dots, respectively, while the resulting
linear lines correspond to each group were presented by a black and gray lines, respectively. We did not observe any significant correlation
between the methylation ratios to the global change in TL
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gliomagenesis was noticed at all age groups compared
to control patients, which also makes these CpG sites
good biomarker candidates for early detection of dis-
ease. We cross-validated the MSP results with the
change in subtelomeric methylation between the groups
using pyrosequencing. Herein, we observed that except
for Chr. 8q and 18p, both the assays were in agreement
with each other for the observed regions in all the chro-
mosomes. In this regard, we would like to consider the
pyrosequencing data as methylation determinant in
Chr. 8q, and 18p, since false positive results are often
obtained in MSP due to mis-priming, high number of
replication cycle, or subtle difference in DNA concen-
tration [41]. Moreover, in pyrosequencing analysis, we
can cover many more CpG islands than MSP. This
might result in significant difference between the final
outcomes between these two methods, irrespective of
the fact that pyrosequencing primers flanked the MSP
sites. Based on these observations, we consider that se-
lective increase in methylation level, identified at
Chr.8q, 21q, and XpYp subtelomeres, may be used as
strong and unequivocal epigenetic marker of glioma.
However, we did not observe any significant difference
in the genome-wide 5-mC % between the control and
diseased group. This also supports the relevance of
using selective changes in the subtelomeric methylation
as the biomarker of the disease.
We have also evaluated the possible effect of altered
subtelomeric methylation on the telomere lengthening,
but did not find any significant correlation. In fact, there
was no remarkable change in TL between the control
and glioma patients. These results corroborate with the
previous finding, where no detectable changes were ob-
served in TL or no correlation between TL and the risk
of glioma was established [42]. In addition, induced de-
methylation in SF767 cells followed by AZA treatment
resulted in insignificant changes in the TL but significant
alterations in the subtelomeric methylation profile. This
confirmed that there may not be a direct correlation
between the subtelomeric methylation and telomere
lengthening in glioma. We believe that this needs whole-
genome DNA methylation sequencing of individual sub-
telomeres at each chromosome, which should be com-
pared with the corresponding length of the telomere.
Although the present study reports the selective increase
in subtelomeric methylation as an epigenetic biomarker
of glioma, the major impasse for implementing this
screening method could lie with the limited access for
brain biopsies in patients. However, we believe that if
the present screening technique could be coupled with
novel tools such as circulating tumor cell collection
method [43], it could serve as the non-invasive platform
for the detection of glioma in patients. Finally, since the
increase in selective subtelomeric methylation level was
observed in patients even with low-grade glioma, this
method can also aid in the early detection of the disease.
Conclusions
Methylation level significantly and invariably increased
at the subtelomeres of Chr. 8q, 21q, and XpYp in pa-
tients with different grades of glioma. The changes in
methylation level are well demonstrated by both the
Fig. 6 a Induced demethylation was recognized with the increased band intensity of the amplicons against the unmethylation (U)-specific
primers in AZA-treated SF-767 cell line. b The adjacent bar chart, extracted from the gel image expresses the change in demethylation ratio
between the non-treated and AZA-treated replica. The demethylation ratio at each of the subtelomeres was increased in comparison to the
untreated replica. Nonetheless, we did not observe any significant alteration in TL after treatment with AZA (c).
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MSP and pyrosequencing data and are independent of
demographic and clinicopathologic features of the pa-
tients. Changes in methylation levels at the subtelomeric
sites among glioma patients hence could be proposed as
potential epigenetic biomarkers of the disease regardless
of their insignificant correlation with TL. The overall
findings of our study also provide a solid platform to
further investigate the additional epigenetic interplay at
the subtelomeric loci during diseased state.
Additional file
Additional file 1: Supplementary information. This contains
Tables S1–S2, Figures S1–S3, and supplementary note.
Abbreviations
5-mC: 5-methylcytosine; ALT: alternative lengthening of telomeres;
AZA: 5-azacytidine; Chr: chromosome; M: methylation; MGMT: O6-methylguanine
DNA-methyltransferase; MSP: methylation specific polymerase chain reaction;
T/S: relative telomere length; TL: telomere length; TERRA: telomere
repeat-containing RNA; U: unmethylation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
SRC and JI have conceptualized the idea. SRC did perform all the
methylation assays with assistance from JM. JL and YC have supplied the
DNA samples. YC performed AZA treatment to the cells and took part in
data analysis. SRC has performed the TL measurements in assistance from YC




Authors are thankful to Chiao-Ling Lo, Department of Anatomy & Cell
Biology, Indiana University School of Medicine, Indianapolis, IN 46202, for
helping in designing the pyrosequencing primers. This work was supported
by the W.M. Keck Foundation grant and the National Science Foundation
(grant #1249315). The Purdue Center for Cancer Research (P30CA023168) is
acknowledged.
Author details
1Department of Biological Engineering, Center for Cancer Research, Purdue
University, West Lafayette, IN 47906, USA. 2Department of Biological Sciences,
Purdue University, West Lafayette, IN 47906, USA. 3Department of
Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan
410008, China.
Received: 29 June 2015 Accepted: 22 September 2015
Reference
1. Áfra D, Baron B, Bonadonna G, Burdett S, Parmar MKB, Stenning SP, et al.
Chemotherapy in adult high-grade glioma: a systematic review and
meta-analysis of individual patient data from 12 randomised trials. Lancet.
2002;359(9311):1011–8.
2. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, et al.
Malignant glioma: genetics and biology of a grave matter. Genes Dev.
2001;15(11):1311–33.
3. Krex D, Klink B, Hartmann C, Von Deimling A, Pietsch T, Simon M, et al.
Long-term survival with glioblastoma multiforme. Brain. 2007;I30:2596–606.
4. Sturm D, Bender S, Jones DTW, Lichter P, Grill J, Becher O, et al. Paediatric
and adult glioblastoma: multiform (epi) genomic culprits emerge. Nat Rev
Cancer. 2014;14:92–107.
5. Duffner PK, Krischer JP, Burger PC, Cohen ME, Backstrom JW, Horowitz ME,
et al. Treatment of infants with malignant gliomas: the Pediatric Oncology
Group experience. J Neurooncol. 1996;28(2–3):245–56.
6. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.
7. Zheng S, Houseman EA, Morrison Z, Wrensch MR, Patoka JS, Ramos C, et al.
DNA hypermethylation profiles associated with glioma subtypes and EZH2
and IGFBP2 mRNA expression. Neuro Oncol. 2011;13(3):280–9.
8. Kurscheid S, Bady P, Sciuscio D, Samarzija I, Shay T, Vassallo I, et al.
Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are
associated with expression of a stem cell related HOX-signature in
glioblastoma. Genome Biol. 2015;16(16):1–15.
9. Tabu K, Sasai K, Kimura T, Wang L, Aoyanagi E, Kohsaka S, et al. Promoter
hypomethylation regulates CD133 expression in human gliomas. Cell Res.
2008;18(10):1037–46.
10. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of
O6-methylguanine methyltransferase (MGMT) promoter methylation with
clinical outcomes in glioblastoma and clinical strategies to modulate MGMT
activity. J Clin Oncol. 2008;25(25):4189–99.
11. Hegi ME, Diserens AC, Gorlia T, Hamou MF, Tribolet ND, Weller M, et al.
MGMT gene silencing and benefit from temozolomide in glioblastoma. N
Engl J Med. 2005;352:997–1003.
12. Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA,
et al. Induction of MGMT expression is associated with temozolomide
resistance in glioblastoma xenografts. Neuro Oncol. 2009;11(3):281–91.
13. Dubuc AM, Mack S, Unterberger A, Northcott PA, Taylor MD. The epigenetic
of brain tumor. Methods Mol Biol. 2012;863:139–53.
14. Maleszewska M, Kaminska B. Is glioblastoma an epigenetic malignancy?
Cancers (Basel). 2013;5(3):1120–39.
15. Nagarajan RP, Costello JF. Molecular epigenetics and genetics in neuro-oncology.
Neurotherapeutics. 2009;6(3):436–46.
16. Blackburn EH. Structure and function of telomeres. Nature. 1991;350:569–73.
17. De Lange T. Shelterin: the protein complex that shapes and safeguards
human telomeres. Genes Dev. 2005;19:2100–10.
18. Riethman H, Ambrosini A, Paul S. Human subtelomere structure and
variation. Chromosome Res. 2005;13(5):505–15.
19. Wang T, Wu H, Li Y, Szulwach KE, Lin L, Li X, et al. Subtelomeric hotspots of
aberrant 5-hydroxymethylcytosine-mediated epigenetic modifications
during reprogramming to pluripotency. Nat Cell Biol. 2013;15(6):700–11.
20. Buxton JL, Suderman M, Pappas JJ, Borghol N, McArdle W, Blakemore
A. Human leukocyte telomere length is associated with DNA
methylation levels in multiple subtelomeric and imprinted loci. Sci Rep.
2014;4(4954):1–8.
21. Ng LJ, Cropley JE, Pickett HA, Reddel RR, Suter CM. Telomerase activity is
associated with an increase in DNA methylation at the proximal
subtelomere and a reduction in telomeric transcription. Nucleic Acids Res.
2009;37(4):1152–9.
22. Nergadze SG, Farnung BO, Wischnewski H, Khoriauli L, Vitelli V, Chawla R,
et al. CpG-island promoters drive transcription of human telomeres. RNA.
2009;15:2186–94.
23. Arnoult N, Van Beneden A, Decottignies A. Telomere length regulates
TERRA levels through increased trimethylation of telomeric H3K9 and HP1
alpha. Nat Struct Mol Biol. 2012;19:948–56.
24. Lu F, Liu Y, Jiang L, Yamaguchi S, Zhang Y. Role of Tet proteins in enhancer
activity and telomere elongation. Gene Dev. 2014;28:2103–19.
25. Guan JZ, Guan WP, Maeda T, Makino N. Analysis of telomere length and
subtelomeric methylation of circulating leukocytes in women with
Alzheimer’s disease. Aging Clin Exp Res. 2013;25(1):17–23.
26. Gadalla SM, Katki HA, Shebl FM, Giri N, Alter BP, Savage SA. The relationship
between DNA methylation and telomere length in dyskeratosis congenita.
Aging Cell. 2012;11(1):24–8.
27. Oh BK, Um TH, Choi GH, Park YN. Frequent changes in subtelomeric DNA
methylation patterns and its relevance to telomere regulation during
human hepatocarcinogenesis. Int J Cancer. 2011;128(4):857–68.
28. Benetti R, Garcia-Cao M, Blasco MA. Telomere length regulates the
epigenetic status of mammalian telomeres and subtelomeres. Nat Genet.
2007;39:243–50.
29. Shukla S, Pia Patric IR, Thinagararjan S, Srinivasan S, Mondal B, Hegde AS.
A DNA methylation prognostic signature of glioblastoma: identification of
NPTX2-PTEN-NF-κB nexus. Cancer Res. 2013;73(22):6563–73.
30. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids
Res. 2002;10(e47):1–6.
Choudhury et al. Clinical Epigenetics  (2015) 7:107 Page 10 of 11
31. O’Callaghan NJ, Dhillon VS, Thomas P, Fenech MA. Quantitative real-time
PCR method for absolute telomere length. Biotechniques. 2008;44:807–9.
32. Rampazzo E, Bertorelle R, Serra L, Terrin L, Candiotto C, Pucciarelli S, et al.
Relationship between telomere shortening, genetic instability, and site of
tumor origin in colorectal cancers. Br J Cancer. 2010;102(8):1300–5.
33. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol
Genet. 2001;10(7):677–85.
34. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific
association human telomerase activity with immortal cells and cancer.
Science. 1994;266(5193):2011–5.
35. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, et al.
Alternative lengthening of telomeres and survival in patients with
glioblastoma multiforme. Lancet. 2003;361(9360):836–8.
36. Silvestre DC, Pineda JR, Hoffschir F, Studler JM, Mouthon MA, Pflumio F,
et al. Alternative lengthening of telomeres in human glioma stem cells.
Stem Cells. 2011;29(3):440–51.
37. Gonzalo S, Jaco I, Fraga MF, Chen T, Li E, Esteller M, et al. DNA
methyltransferases control telomere length and telomere recombination in
mammalian cells. Nat Cell Biol. 2006;8(4):416–24.
38. Tilman G, Loriot A, Van Beneden A, Arnoult N, Londoño-Vallejo JA, De Smet
C, et al. Subtelomeric DNA hypomethylation is not required for telomeric
sister chromatid exchanges in ALT cells. Oncogene. 2009;28(14):1682–93.
39. Episkopou H, Draskovic I, Van Beneden A, Tilman G, Mattiussi M, Gobin M,
et al. Alternative lengthening of telomeres is characterized by reduced
compaction of telomeric chromatin. Nucleic Acids Res. 2014;42(7):4391–405.
40. Murnane JP, Sabatier L, Marder BA, Morgan WF. Telomere dynamics in an
immortal human cell line. EMBO J. 1994;13:4953–62.
41. Shaw RJ, Akufo-Tetteh EK, Risk JM, Field JK, Liloglou T. Methylation
enrichment pyrosequencing: combining the specificity of MSP with
validation by pyrosequencing. Nucleic Acids Res. 2006;34(11):e78.
42. Walcott F, Rajaraman P, Gadalla SM, Inskip PD, Purdue MP, Albanes D, et al.
Telomere length and risk of glioma. Cancer Epidemiol. 2013;37(6):935–8.
43. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells:
approaches to isolation and characterization. J Cell Biol. 2011;192(3):373–82.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Choudhury et al. Clinical Epigenetics  (2015) 7:107 Page 11 of 11
